TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

$510,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Implementation of the Inflation ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...

Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to ...

Pacira BioSciences (PCRX) announced two key appointments to its executive leadership team. Brendan Teehan has been named Chief Commercial ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ...

Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected] Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 [email protected] Source ...